Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
16 août 2024 06h00 HE
|
Immuron Limited
Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16,...
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
15 août 2024 18h14 HE
|
Immuron Limited
MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that...
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect
07 août 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be...
Immuron announces record Travelan® sales globally, Australia and USA
15 juil. 2024 08h00 HE
|
Immuron Limited
Sales Highlights: Global• FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp) • June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter Australia• FY 2024 AUD$3.7...
Immuron requests pre-IND meeting for IMM-529 with FDA filing
02 juil. 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that...
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
05 juin 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that...
Immuron CEO Steven Lydeamore to present at Peak Sky High
31 mai 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief...
Immuron Board Changes
31 mai 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston...
Immuron Limited to Present at the Emerging Growth Conference
07 mai 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite individual...
Immuron Director Resignation
03 mai 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen...